{"id":6602,"date":"2021-03-18T08:48:18","date_gmt":"2021-03-18T07:48:18","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf"},"modified":"2021-03-18T08:51:46","modified_gmt":"2021-03-18T07:51:46","slug":"20211103_maat_ebmt-platform-presentation-acceptance-fr-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-topline-results-from-phase-2-heracles-clinical-trial-with-lead-microbiome-ecosystem-therapy-maat013-in-patients-with-acute-graft-versus-host-disease\/20211103_maat_ebmt-platform-presentation-acceptance-fr-2\/","title":{"rendered":"20211103_MaaT_EBMT-platform-presentation-acceptance FR"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-6602","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>20211103_MaaT_EBMT-platform-presentation-acceptance FR | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf\",\"name\":\"20211103_MaaT_EBMT-platform-presentation-acceptance FR | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2021-03-18T07:48:18+00:00\",\"dateModified\":\"2021-03-18T07:51:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease\",\"item\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-topline-results-from-phase-2-heracles-clinical-trial-with-lead-microbiome-ecosystem-therapy-maat013-in-patients-with-acute-graft-versus-host-disease\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"20211103_MaaT_EBMT-platform-presentation-acceptance FR\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"20211103_MaaT_EBMT-platform-presentation-acceptance FR | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf","name":"20211103_MaaT_EBMT-platform-presentation-acceptance FR | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2021-03-18T07:48:18+00:00","dateModified":"2021-03-18T07:51:46+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease","item":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-positive-topline-results-from-phase-2-heracles-clinical-trial-with-lead-microbiome-ecosystem-therapy-maat013-in-patients-with-acute-graft-versus-host-disease\/"},{"@type":"ListItem","position":3,"name":"20211103_MaaT_EBMT-platform-presentation-acceptance FR"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf'><img loading=\"lazy\" decoding=\"async\" width=\"126\" height=\"300\" src=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-126x300.jpg\" class=\"attachment-medium size-medium\" alt=\"\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"sizes":{"thumbnail":{"file":"20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-63x150.jpg","width":63,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-63x150.jpg"},"medium":{"file":"20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-126x300.jpg","width":126,"height":300,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-126x300.jpg"},"large":{"file":"20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-430x1024.jpg","width":430,"height":1024,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf-430x1024.jpg"},"full":{"file":"20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf.jpg","width":1058,"height":2520,"mime_type":"application\/pdf","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR-pdf.jpg"}}},"post":6604,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/03\/20211103_MaaT_EBMT-platform-presentation-acceptance-FR.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/6602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=6602"}]}}